Stay updated on Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page footer’s revision label has been updated from **v3.5.2** to **v3.5.3**, indicating a change to the site version rather than the study information.SummaryDifference0.0%

- Check8 days agoChange DetectedAdded Revision: v3.5.2. Removed Revision: v3.5.0.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedThe page now displays Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check51 days agoChange DetectedRevision history updated to add v3.4.3 and remove v3.4.2.SummaryDifference0.0%

- Check73 days agoChange DetectedFallopian tube cancer added to the study keywords; the record revision updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check80 days agoChange DetectedAdded Primary peritoneal carcinoma to the terminology and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.1%

Stay in the know with updates to Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.